姜黄素纳米粒(NanoCurc)联合索拉非尼对肝细胞癌（HCC）的协同抑制作用

被引：2

作者：

胡博

孙超

孙鼎

孙云帆

徐泱

机构：

[1] 复旦大学附属中山医院肝癌研究所

来源：

复旦学报(医学版) | 2014年 / 02期

关键词：

肝细胞癌(HCC); 姜黄素纳米粒(NC); 索拉非尼; 基质金属蛋白酶-9(MMP-9);

D O I：

暂无

中图分类号：

R735.7 [肝肿瘤];

学科分类号：

摘要：

目的探讨姜黄素纳米粒(NanoCurcTM,NC)单药或联合索拉非尼对人肝细胞癌(hepatocellular carcinoma,HCC)的作用。方法采用体外细胞增殖检测试剂盒(CCK-8)、体外划痕试验和Transwell侵袭试验法检测NC和/或索拉非尼对肝癌细胞株MHCCLM3增殖、迁移、侵袭能力的影响;应用流式细胞术分析其对细胞凋亡的作用。建立裸鼠MHCCLM3原位移植模型并观察NC和/或索拉非尼对肿瘤大小和肺转移率的影响。应用RTPCR、ELISA、Western blot法检测基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)、基质金属蛋白酶抑制剂-1(tissue inhibitor of metalloproteinase-1,TIMP-1)、细胞外信号调节激酶1/2(ERK1/2)mRNA或相应蛋白表达变化;并测定ERK1/2的磷酸化变化。结果 NC与索拉非尼联合应用可显著抑制HCC体外增殖和侵袭能力(P<0.01),抑制体内肿瘤生长和肺转移(P<0.01)。单独应用NC和索拉非尼时肺转移率分别为50.0%和66.7%,两者联合用药时则显著降低至16.7%。两药联合应用可协同抑制ERK磷酸化,从而下调MMP-9的表达。结论 NC联合索拉非尼可通过协同诱导细胞凋亡、抑制MMP-9的表达而抑制肝癌生长和转移。

引用

页码：143 / 148

页数：6

共 6 条

[1] Hypoxia-Mediated Sorafenib Resistance Can Be Overcome by EF24 Through Von Hippel-Lindau Tumor Suppressor-Dependent HIF-1α Inhibition in Hepatocellular Carcinoma [J].

Liang, Yingjian ;

Zheng, Tongsen ;

Song, Ruipeng ;

Wang, Jiabei ;

Yin, Dalong ;

Wang, Luoluo ;

Liu, Haitao ;

Tian, Lantian ;

Fang, Xiang ;

Meng, Xianzhi ;

Jiang, Hongchi ;

Liu, Jiaren ;

Liu, Lianxin .

HEPATOLOGY, 2013, 57 (05) :1847-1857

[2]

Nanocapsulated curcumin: Oral chemopreventive formulation against diethylnitrosamine induced hepatocellular carcinoma in rat[J] . Debasree Ghosh,Somsubhra Thakur Choudhury,Swarupa Ghosh,Ardhendu K. Mandal,Sibani Sarkar,Aparajita Ghosh,Krishna Das Saha,Nirmalendu Das.Chemico-Biological Interactions . 2011 (3)

[3]

Hepatocellular Carcinoma: Current Management and Perspectives for the Future[J] . Nuh N. Rahbari,Arianeb Mehrabi,Nathan M. Mollberg,Sascha A. Müller,Moritz Koch,Markus W. Büchler,Jürgen Weitz.Annals of Surgery . 2011 (3)

[4]

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J] . Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan.Lancet Oncology . 2009 (1)

[5] From exotic spice to modern drug? [J].

Singh, Seema .

CELL, 2007, 130 (05) :765-768

[6]

Report of the 15th follow-up survey of primary liver cancer[J] . Iwao Ikai,Yuji Itai,Kiwamu Okita,Masao Omata,Masamichi Kojiro,Kenichi Kobayashi,Yasuni Nakanuma,Shunji Futagawa,Masatoshi Makuuchi,Yoshio Yamaoka.Hepatology Research . 2003 (1)

← 1 →